April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here